v3.26.3
Collaboration and license agreements (Tables)
 9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of allocation of transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of September 30, 2026 (in thousands):
Transaction
Price
Allocated		Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$21,491 $1,351 
Option rights2,491 2,491 
Total$23,982 $3,842 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements for the three and nine months ended September 30, 2026 and 2025 in the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue from collaboration agreements:
Roche DAC Agreement$3,852 $— $6,518 $— 
MKDG Agreement1,921 3,360 5,516 9,941 
Betta Agreements3 27 23 541 
2018 Roche Agreement2,692 2,001 7,204 6,429 
Biogen Agreement— 2,000 2,000 2,000 
Merck Agreement— 3,842 — 6,020 
Total revenue from collaboration agreements$8,468 $11,230 $21,261 $24,931 
Schedule of financial information related to collaboration and license agreements
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of September 30, 2026 (in thousands):
Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:
Roche DAC Agreement$— $13,482 $— $13,482 
MKDG Agreement1,023 1,254 — 1,254 
Betta Agreements6 938 13,765 14,703 
2018 Roche Agreement376 3,842 — 3,842 
Biogen Agreement— — — — 
Total$1,405 $19,516 $13,765 $33,281 
Financial information related to the collaboration and license agreements consisted of the following in the Company’s condensed consolidated balance sheet as of December 31, 2025 (in thousands):
Accounts
Receivable		Deferred Revenue,
Current		Deferred Revenue,
Net of Current		Deferred Revenue,
Total
Supplemental information:
MKDG Agreement$1,892 $3,913 $— $3,913 
Betta Agreements9 531 14,194 14,725 
2018 Roche Agreement500 8,049 1,647 9,696 
Total$2,401 $12,493 $15,841 $28,334 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements for the three and nine months ended September 30, 2026 and 2025 is as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenue recognized that was included in the contract liability at the beginning of the period$7,596 $6,581 $10,036 $13,822